Aug 19 (Reuters) - Novo Nordisk A/S NOVOb.CO:
HEALTH CANADA APPROVES OZEMPIC® TO REDUCE THE RISK OF SUSTAINED EGFR DECLINE, END-STAGE KIDNEY DISEASE, AND CARDIOVASCULAR DEATH IN ADULTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE
NOVO NORDISK CANADA: HEALTH CANADA'S CKD INDICATION FOR OZEMPIC IS BASED ON RESULTS OF FLOW TRIAL
Further company coverage: [NOVOb.CO]